Windtree Therapeutics, Inc. Shareholders Equity (Total)

Shareholders Equity (Total) of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shareholders Equity (Total) growth rates and interactive chart. Shareholder equity, also referred to as shareholders' equity and stockholders' equity, it a corporation's owners' residual claim after debts have been paid. Equity is equal to a firm's total assets minus its total liabilities. It is found on a company's balance sheet and it's the total equity available to common shareholders (after accounting for preferred equity). Also called book value or net book value.


Highlights and Quick Summary

  • Shareholders Equity (Total) for the quarter ending June 29, 2020 was $83.5 Million (a 19.07% increase compared to previous quarter)
  • Year-over-year quarterly Shareholders Equity (Total) increased by 57.25%
  • Annual Shareholders Equity (Total) for 2019 was $74.9 Million (a 10.01% increase from previous year)
  • Annual Shareholders Equity (Total) for 2018 was $68.1 Million (a -384.76% decrease from previous year)
  • Annual Shareholders Equity (Total) for 2017 was $-23.9 Million (a -17.03% decrease from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shareholders Equity (Total) of Windtree Therapeutics, Inc.

Most recent Shareholders Equity (Total)of WINT including historical data for past 10 years.

Interactive Chart of Shareholders Equity (Total) of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Shareholders Equity (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $83.46 $70.09
2019 $74.94 $53.07 $58.27 $63.0 $74.94
2018 $68.11 $-31.33 $-28.38 $-28.07 $68.11
2017 $-23.92 $-37.45 $-32.18 $-25.76 $-23.92
2016 $-28.83 $-22.85 $-15.22 $-4.98 $-28.83
2015 $8.27 $17.89 $-3.08 $7.81 $8.27
2014 $19.2 $28.97 $39.21 $48.81 $19.2
2013 $58.5 $5.48 $16.82 $9.46 $58.5
2012 $17.65 $23.05 $35.7 $42.23 $17.65
2011 $1.26 $4.73 $9.21 $16.87 $1.26
2010 $6.03 $10.1 $18.05 $12.74 $6.03

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.